Leverkusen, October 16, 2014 - Bayer has been confirmed as a leading global company in the pharmaceutical industry when it comes to climate protection. In recognition of its achievements in reducing greenhouse gas emissions and its strategic handling of the consequences of climate change, the Group has once again been included in "The A List: The CDP Climate Performance Leadership Index." To compile the 2014 list, nearly 2,000 of the world's largest listed companies were assessed, and 187 groups from various industries were included in the climate index.

The non-governmental organization "Carbon Disclosure Project" (CDP) conducted the assessment on behalf of 767 institutional investors, who, according to CDP figures, represent an investment volume of USD 92 trillion, or more than a third of global investments. The detailed questionnaire used can be found at www.cdproject.net. This provides investors with a unique data basis in terms of climate protection, which they can use in their investment decisions.

"We are delighted by our renewed listing in this important climate index," said Michael König, member of the Bayer Board of Management responsible for Human Resources, Technology and Sustainability. "Climate protection and dealing with the consequences of climate change remain an ongoing task - from a political, social and economic perspective." Bayer also received the top grade for the transparency of the data it provided in the course of the assessment.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2013, the Group employed 113,200 people and had sales of EUR 40.2 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 3.2 billion. For more information, go to www.bayer.com.

More information and the corporate questionnaire can be found at:
www.cdproject.net

For Social Media Users:
Visit us on Facebook: www.facebook.com/Bayer
Follow us on Twitter: twitter.com/Bayer

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

distributed by